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ABSTRACT
G protein-coupled oestrogen receptor 1 (GPER), also called G protein-coupled 
receptor 30 (GPR30), is attracting considerable attention for its potential role in breast 
cancer development and progression. Activation by oestrogen (17β-oestradiol; E2) 
initiates short term, non-genomic, signalling events both in vitro and in vivo. Published 
literature on the prognostic value of GPER protein expression in breast cancer indicates 
that further assessment is warranted. We show, using immunohistochemistry on a 
large cohort of primary invasive breast cancer patients (n=1245), that low protein 
expression of GPER is not only significantly associated with clinicopathological 
and molecular features of aggressive behaviour but also significantly associated 
with adverse survival of breast cancer patients. Furthermore, assessment of GPER 
mRNA levels in the METABRIC cohort (n=1980) demonstrates that low GPER mRNA 
expression is significantly associated with adverse survival of breast cancer patients. 
Using artificial neural networks, genes associated with GPER mRNA expression were 
identified; these included notch-4 and jagged-1. These results support the prognostic 
value for determination of GPER expression in breast cancer.
INTRODUCTION
Breast cancer is the most common cancer in women, 
with over 1.7 million cases diagnosed worldwide in 2012 
[1]. The female sex hormone, oestrogen (17β-oestradiol; 
E2), has an important role in breast cancer development 
and progression, with effects mediated through nuclear 
oestrogen receptors (ERɑ and ERβ) which act directly as 
transcription factors to regulate the expression of genes 
able to alter cell survival and growth.
G protein-coupled oestrogen receptor 1 (GPER) or G 
protein-coupled receptor 30 (GPR30) is a G protein-coupled 
receptor first cloned in 1996 [2] and first described in breast 
cancer in the ER positive MCF-7 cell line [3]. GPER has a 
potential role in breast cancer although controversies exist 
over its subcellular localisation, and mechanism of receptor 
activation [4–6]. GPER has been shown to bind E2 to 
initiate short term, non-genomic, signalling events both in 
vitro [7–9] and in vivo [10]. Expression of GPER has also 
been shown to be associated with ER expression and status 
in a number of studies [11] and to attenuate the growth of 
ER positive breast cancer [11]. Tamoxifen has been shown 
to act as a GPER agonist, and GPER has been implicated 
in tamoxifen resistance via its upregulation in a tamoxifen 
resistant breast cancer cell line which results in the activation 
of epidermal growth factor receptor (EGFR) [12].
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GPER activation upregulates interleukin-1 
receptor-1 (IL1R1) expression on breast cancer cells 
and interleukin (IL)-1β expression on cancer associated 
fibroblasts in a signalling loop to encourage invasive 
features of breast cancer [13]. GPER also supresses 
migration and angiogenesis of ER negative triple negative 
breast cancer by inhibiting nuclear factor (NF)-κB/
interleukin (IL)-6 signals [14].
GPER expression in breast cancer has been assessed 
in a number of studies; however, these have proved 
ambiguous. High GPER protein expression is associated 
with increased distant disease free survival in ER-positive 
lymph node negative disease [15], presence of metastasis 
[16] and adverse relapse free survival of patients 
treated with tamoxifen [17]. GPER mRNA expression 
is significantly lower in tumour tissue in comparison to 
normal tissue, indicating that GPER acts as a tumour 
suppressor [18, 19]. Recently, a large assessment of 
GPER mRNA expression in 781 primary breast tumours 
demonstrated that high GPER expression is associated 
with favourable overall survival and that GPER silencing 
may be due to hyper-methylation of the flanking regions 
of the upstream CpG island [19]. However a smaller 
study of 167 breast cancer patients showed no association 
between mRNA expression and patient survival [20].
This study sought to investigate the expression 
levels of GPER mRNA and protein in large well 
characterised cohorts of breast cancer patients and assess 
for association with survival.
RESULTS
GPER protein staining location and frequency
GPER expression was observed in both the nucleus 
and the cytoplasm of tumour cells. Staining varied from 
weak to intense, with heterogeneity observed between 
adjacent tumour cells. Representative photomicrographs 
are shown in Figure 1. Cytoplasmic GPER expression had 
a median H-score of 10 and ranged from 0-290. Nuclear 
GPER expression had a median score of 0 and ranged 
from 0-100. X-tile was used to generate cut points for 
assessment based on breast cancer specific survival with 
a cut point of 25 for cytoplasmic GPER expression with 
73.6% of cases (916/1244) demonstrating low expression; 
nuclear GPER expression had a cut point of 5 with 70.0% 
of cases (869/1241) demonstrating low expression. A 
proportion of cores within the tissue microarray could not 
be assessed as they were missing or cores had insufficient 
tumour cells.
Relationship between GPER protein expression 
and clinicopathological variables
High nuclear GPER expression was significantly 
associated with smaller tumours (χ2=22.5; d.f.=1; 
P<0.001), lower tumour grade (χ2=23.6; d.f.=2; P<0.001), 
lower NPI value (χ2=22.0; d.f.=2; P<0.001), ER positive 
tumours (χ2=4.8; d.f.=1; P=0.029); and with tumour 
stage (χ2=7.5; d.f.=2; P=0.024) (Table 1). No significant 
associations between cytoplasmic GPER expression and 
clinicopathological variables were observed (Table 1).
Association between GPER protein expression 
and survival
Low expression of cytoplasmic GPER was 
significantly associated with adverse breast cancer-
specific survival (P=0.002) (Figure 2A). In multivariate 
Cox regression cytoplasmic GPER expression remained 
significantly associated (P=0.023) with breast cancer 
survival when including the potential confounding factors 
of tumour size, tumour stage and grade, NPI value, ER, 
PgR and HER2 status and Lymph node status (with 
individual Kaplan–Meier statistics of P<0.001, P<0.001, 
P<0.001, P<0.001, P=0.002, P<0.001, P<0.001, P<0.001 
respectively) (Table 2). Expression of GPER in the 
nucleus was not significantly associated with breast cancer 
specific-survival (P=0.067) (Figure 2B). In addition 
to disease specific survival, cytoplasmic expression of 
GPER was significantly associated with adverse relapse 
free interval (P=0.023), but not nuclear GPER expression 
(P=0.057) (Figure 3A and 3B).
Interestingly, low expression of cytoplasmic GPER 
was significantly associated with adverse survival of 
patients who received endocrine therapy (P=0.003) 
(Figure 4B); whereas no association was observed in 
breast cancer-specific survival in patients who did not 
receive endocrine therapy (P=0.205) (Figure 4A). There 
was no difference observed in breast cancer specific 
survival of patients receiving endocrine therapy dependent 
upon nuclear GPER expression.
GPER mRNA expression and clinicopathological 
variables
Data was available for two GPER probes in the 
Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) data set: probe 1 
(ILMN_1795298) and probe 2 (ILMN_2384056). Both 
were assessed independently for associations with 
clinicopathological variables and patient survival (Table 
3) and were categorised into low and high groups using 
X-tile. Both GPER probe 1 and probe 2 demonstrated 
that low GPER expression were associated with basal 
and HER2 PAM50 subtype (χ2=207.4; d.f.=4; P<0.001 
and χ2=177.5; d.f.=4; P<0.001 respectively). Low GPER 
mRNA expression was associated with P53 mutation 
status (χ2=19.7; d.f.=1; P<0.001 and χ2=33.4; d.f.=1; 
P<0.001 for probe 1 and 2 respectively), stage (χ2=11.4; 
d.f.=4; P=0.023 and χ2=11.1; d.f.=4; P=0.025 for probe 1 
and 2 respectively), larger tumour size (χ2=16.2; d.f.=1; 
P<0.001 and χ2=16.9; d.f.=1; P<0.001 for probe 1 and 
2 respectively), higher tumour grade (χ2=83.0; d.f.=2; 
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P<0.001 and χ2=87.3; d.f.=2; P<0.001 for probe 1 and 2 
respectively) and ER negative tumours (χ2=119.1; d.f.=1; 
P<0.001 and χ2=130.3; d.f.=1; P<0.001 for probe 1 and 2 
respectively).
Association between GPER mRNA expression 
and patient survival
Low GPER probe 1 and probe 2 mRNA expression 
was significantly associated with adverse overall survival 
of the breast cancer cohort; (P=0.004) and (P=0.001) 
respectively (Figure 5A and 5B).
Comparison between GPER mRNA and protein 
expression
There were 194 tumours in this study that were 
assessed for GPER protein expression and for GPER 
mRNA expression as part of the METABRIC cohort. 
Cytoplasmic expression of GPER was not correlated with 
GPER probe 1 or probe 2 mRNA expression (P=0.824, 
R2=-0.016 and P=0.868, R2=0.012 respectively. Nuclear 
GPER expression was not correlated with GPER probe 
1 mRNA expression (P=0.079, R2=-0.126), but was 
correlated with GPER probe 2 mRNA expression 
(P=0.024, R2=0.162).
Expression profiling
The gene expression data was analysed using an 
artificial neural network approach that uses a machine 
learning based data mining algorithm [21]. A rank order of 
all the genes was produced based on the minimum average 
root mean squared error. The top 200 transcripts were 
selected for GPER probe 1 and probe 2, and 84 common 
transcripts were identified. The top 20 unique transcripts 
include myomesin 1, ribosomal protein L39 like, vinexin 
beta and high density lipoprotein binding protein (Table 
4). Some of these transcripts were assessed further using 
an ANOVA based approach to determine their relationship 
with GPER mRNA expression. A positive association was 
observed between both GPER probes and notch-4 (both 
P<0.001), jagged-1 (both P<0.001), claudin-5 (both 
P<0.001), CD34 (both P<0.001) and adenylate cyclase 4 
(both P<0.001).
DISCUSSION
In this study, we describe how GPER protein 
and mRNA expression levels at the time of surgery are 
associated with breast cancer patient survival and various 
clinicopathological variables. Low cytoplasmic GPER 
protein expression was significantly associated with 
adverse breast cancer specific survival (P=0.002) and 
remained so in multivariate analysis including various 
potentially confounding factors, such as ER status. GPER 
expression within the nucleus was not associated with 
patient survival. It would be interesting to hypothesise 
over the importance of non-genomic actions of GPER; 
however, this study assessed expression of GPER with no 
measure of its activity.
Previously published studies have investigated 
GPER expression in patient samples to show a number of 
associations with clinicopathological variables, however 
the results from these have not always been in agreement. 
One of the largest studies to date investigated 981 primary 
invasive breast carcinomas, including investigation of 
nuclear and cytoplasmic GPER staining and is in consensus 
with the current findings. This study demonstrated that 
low expression of GPER was significantly associated 
with adverse patient survival and that there was no 
association with nuclear GPER expression and patient 
Figure 1: Representative photomicrographs following immunohistochemical staining of (A) negative nuclear and cytoplasmic 
GPER staining; (B) positive nuclear staining; (C) positive cytoplasmic staining in breast cancer specimens. Photomicrographs are shown 
at 100x magnification with 200x magnification inset box where the scale bar represents 100μm.
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Table 1: Associations between the expression of cytoplasmic and nuclear GPER determined by 
immunohistochemistry with clinicopathological variables 
Cytoplasmic GPER Nuclear GPER
low high P value low high P value
Patient age 40 years or less 86 (6.9%) 30 (2.4%)
0.893
87 (7.0%) 29 (2.3%)
0.224
Above 40 years 829 (66.7%) 298 (24.0%) 782 (63.1%) 342 (27.6%)
Tumour size 2cm or less 538 (43.5%) 203 (16.4%)
0.349
480 (38.9) 259 (21.0%)
<0.001
Greater than 2cm 372 (30.1%) 124 (10.0%) 384 (31.1%) 111 (9.0%)
Tumour stage 1 559 (45.2%) 195 (15.8%)
0.608
516 (41.8%) 235 (19.0%)
0.0242 267 (21.6%) 105 (8.5%) 279 (22.6%) 94 (7.6%)
3 84 (6.8%) 27 (2.2%) 69 (5.6%) 41 (3.3%)
Tumour grade 1 135 (10.9%) 64 (5.2%)
0.131
116 (9.4%) 83 (6.7%)
<0.0012 308 (24.9%) 107 (8.6%) 278 (22.5%) 135 (10.9%)
3 467 (37.8%) 156 (12.6%) 470 (38.1%) 152 (12.3%)
NPI less than 3.4 262 (21.2%) 106 (8.6%)
0.336
223 (18.1%) 144 (11.7%)
<0.0013.4-5.4 469 (14.3%) 636 (51.5%) 465 (37.7%) 169 (13.7%)
Greater than 5.4 177 (14.3%) 231 (18.7%) 175 (14.2%) 56 (4.5%)
Basal status Non basal 668 (57.6%) 244 (21.1%)
0.807
646 (55.8%) 264 (22.8%)
0.868
Basal 179 (15.4%) 68 (5.9%) 174 (15.0%) 73 (6.3%)
ER status Negative 233 (19.4%) 94 (7.8%)
0.229
244 (20.3%) 82 (6.8%)
0.029
Positive 655 (54.4%) 222 (18.4%) 598 (49.8%) 277 (23.1%)
PgR status Negative 373 (31.8%) 135 (11.5%)
0.979
369 (31.5%) 139 (11.9%)
0.218
Positive 488 (41.6%) 176 (15.0%) 459 (39.2%) 203 (17.4%)
HER2 status Negative 771 (63.6%) 276 (22.8%)
0.805
725 (60.0%) 320 (26.5%)
0.105
Positive 120 (9.9%) 45 (3.7%) 124 (10.3%) 40 (29.8%)
The P values are resultant from Pearson χ2 test of association. ER is oestrogen receptor and PgR is progesterone receptor.
Figure 2: Kaplan-Meier analysis of breast cancer specific survival showing the impact of low (grey line) and high 
(black line) GPER protein expression within the cytoplasm (A) or the nucleus (B) with significance determined using the log-rank 
test. The numbers shown below the Kaplan-Meier survival curves are the number of patients at risk at the specified month.
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Figure 3: Kaplan-Meier analysis of relapse free survival showing the impact of low (grey line) and high (black line) 
GPER protein expression within the cytoplasm (A) or the nucleus (B) with significance determined using the log-rank test.
Figure 4: Kaplan-Meier analysis of breast cancer specific survival showing the impact of low (grey line) and high 
(black line) GPER protein expression within the cytoplasm in patients who did not receive endocrine therapy (A) or patients that did 
receive endocrine therapy (B) with significance determined using the log-rank test.  The numbers shown below the Kaplan-Meier survival 
curves are the number of patients at risk at the specified month.
Table 2: Cox proportional hazards analysis for overall survival for cytoplasmic GPER expression in breast cancer 
P value Exp(B)
95.0% CI for Exp(B)
Lower Upper
Tumour size 0.031 1.373 1.030 1.831
Tumour stage 0.000 2.441 1.748 3.409
Tumour grade 0.000 1.882 1.390 2.548
NPI 0.984 1.004 0.658 1.533
ER status 0.023 1.475 1.054 2.065
PgR status 0.021 0.699 0.516 0.947
HER2 status 0.000 1.845 1.392 2.444
Lymph node status 0.081 0.701 0.471 1.045
Cytoplasmic GPER1 0.023 0.731 0.558 0.958
Exp(B) is used to denote hazard ratio and 95% CI is used to denote 95% confidence interval.
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Table 3: Associations between the GPER mRNA expressions in the METABRIC cohort with clinicopathological 
variables
GPER probe 1 GPER probe 2
low high P value low high P value
PAM 50 subtype Basal 208 (10.5%) 123 (6.2%)
<0.001
124 (6.3%) 207 (10.5%)
<0.001
HER2 183 (9.3%) 56 (2.8%) 100 (5.1%) 139 (7.0%)
Luminal A 241 (12.2%) 472 (23.9%) 78 (4.0%) 637 (32.3%)
Luminal B 220 (11.1%) 270 (13.7%) 117 (5.9%) 372 (18.9%)
Normal 49 (2.5%) 150 (7.6%) 15 (0.8%) 184 (9.3%)
P53 mutation status Mutated 65 (8.0%) 34 (4.2%)
<0.001
49 (6.0%) 50 (6.1%)
<0.001
Wild type 301 (36.9%) 416 (51.0%) 161 (19.7%) 557 (68.2%)
Stage 0 234 (15.3%) 256 (16.7%)
0.023
113 (7.4%) 376 (24.6%)
0.025
1 141 (9.2%) 229 (15.0%) 64 (4.2%) 307 (20.1%)
2 263 (17.2%) 308 (40.1%) 143 (9.3%) 428 (28.0%)
3 42 (2.7%) 48 (3.1%) 19 (1.2%) 71 (4.6%)
4 2 (0.1%) 8 (0.5%) 0 (0.0%) 10 (0.7%)
Tumour size Less than 2cm 242 (12.4) 379 (19.4%)
<0.001
102 (5.2%) 521 (26.6%)
<0.001
2cm or greater 651 (33.2%) 686 (35.0%) 329 (16.8%) 1007 (51.4%)
Tumour grade 1 48 (2.5%) 121 (6.4%)
<0.001
16 (0.8%) 153 (8.1%)
<0.0012 286 (15.1%) 483 (25.6%) 108 (5.7%) 661 (35.0%)
3 532 (28.2%) 419 (22.2%) 294 (15.6%) 658 (34.8%)
ER status Negative 301 (15.6%) 139 (7.2%)
<0.001
184 (9.5%) 256 (13.2%)
<0.001
Positive 582 (30.1%) 913 (47.2%) 242 (12.5%) 1254 (64.8%)
The P values are resultant from Pearson χ2 test of association. ER is oestrogen receptor and PgR is progesterone receptor.
Figure 5: Kaplan-Meier analysis of overall survival showing the impact of low (grey line) and high (black line) GPER 
mRNA expression with probe 1 (A) or probe 2 (B) with significance determined using the log-rank test. The numbers shown below the 
Kaplan-Meier survival curves are the number of patients at risk at the specified month.
Oncotarget25952www.oncotarget.com
survival; this could not be demonstrated in multivariate 
analysis and was not described in any patient subset [22]. 
No data for systemic therapy was available for the patient 
cohort, so this was not assessed. Other studies have also 
investigated GPER expression, including a study of 481 
breast cancer patients split into two cohorts of pre and 
post-menopausal women, which showed that high GPER 
protein expression was associated with increased distant 
disease free survival of ER positive lymph node negative 
and stage II breast cancer, but did not assess associations 
with disease specific survival [15]. A study investigating 
321 invasive and 40 intraductal breast tumours showed 
associations between GPER expression with tumour size 
and the presence of distant metastasis, but also did not 
assess for associations with disease specific survival [16]. 
Furthermore GPER has been assessed in 323 breast cancer 
patients with a validation cohort of 103 patients to show 
associations between GPER expression and lymph node 
status, and HER2 status; this study also demonstrated an 
association between high GPER expression and adverse 
relapse free survival but no association was observed for 
overall survival [17].
Interestingly, we were also able to demonstrate that 
low cytoplasmic GPER expression was associated with 
adverse survival in breast cancer patients treated with 
endocrine therapy, mainly in the adjuvant setting. This is 
in disagreement with a previous study that demonstrated 
that high GPER expression was associated with adverse 
relapse free survival of breast cancer patients treated with 
tamoxifen but did not describe associations with breast 
cancer specific survival [17].
Associations between GPER protein expression 
and HER2 status, amongst other clinicopathological 
variables, have been described in some studies, however; 
there was no association between cytoplasmic or nuclear 
GPER expression with HER2 in this study. A number of 
associations between clinicopathological variables and 
nuclear GPER expression were observed, but none when 
expression was assessed within the cytoplasm. It is unclear 
as to the function of nuclear GPER expression, there are 
limited reports of nuclear expression in vitro, with studies 
demonstrating concentration of GPER in a compartment 
in close proximity to the nucleus [23], and direct nuclear 
Table 4: The top 20 unique transcripts identified using artificial neural networks as associated with GPER mRNA 
expression in the METABRIC series
Illumina ID Gene Description Molecular class
1 ILMN_1680344 MYOM1 Myomesin 1 Structural protein
2 ILMN_2108357 RPL39L Ribosomal Protein L39 Like Ribosomal subunit
3 ILMN_1789338 SORBS3 Vinexin beta Adhesion molecule
4 ILMN_1726210 GPIHBP1 High density lipoprotein binding protein Unknown
5 ILMN_2172269 TMEM183B Transmembrane protein 183B Transcription regulatory protein
6 ILMN_1676897 HSPA12B Heat shock 70kDa protein 12B Heat shock protein
7 ILMN_2317581 SHANK3 SH2 and multiple ankyrin repeat domains 3 Cytoskeletal associated protein
8 ILMN_1752589 TMEM183A Chromosome 1 open reading frame 37 Unclassified
9 ILMN_1728197 CLDN5 Claudin-5 Adhesion molecule
10 ILMN_1711157 NOTCH4 Notch-4 Cell surface receptor
11 ILMN_1672102 PTPRB Receptor type protein tyrosine phosphatase beta Receptor tyrosine phosphatase
12 ILMN_1748206 C20orf160 C20orf160 protein Unclassified
13 ILMN_1738742 PLAT Tissue type plasminogen activator Serine protease
14 ILMN_1732799 CD34 CD34 Adhesion molecule
15 ILMN_2148944 ADCY4 Adenylate cyclase 4 Adenylate cyclase
16 ILMN_1681356 PDE2A Phosphodiesterase 2A, cGMP-stimulated Phosphodiesterase
17 ILMN_1719236 CDH5 Cadherin-5 Adhesion molecule
18 ILMN_1691376 JAG1 Jagged-1 Cell surface receptor
19 ILMN_1707232 EBF3 Early B-cell factor 3 Transcription factor
20 ILMN_1692340 ZNF662 FLJ45880 protein DNA binding protein
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localisation in breast cancer associated fibroblasts driven 
by changes in N-linked glycosylation [24].
We also investigated the expression of GPER 
mRNA in the METABRIC cohort. Low GPER expression 
was significantly associated with adverse survival of 
breast cancer patients. Two probes representing GPER 
were identified and assessed, probe 1 (ILMN_1795298) 
and probe 2 (ILMN_2384056), both located in the 3’ 
untranslated region. GPER mRNA expression was 
associated with various clinicopathological variables, 
the strongest association being with PAM50 subtype, ER 
status and tumour grade.
Other studies investigating GPER mRNA expression 
in breast cancer have done so in comparison to normal 
mammary tissue to demonstrate lower staining in tumour 
tissue [25]. One of the largest studies to date reported 
GPER expression in 84 normal breast tissues and 781 
primary breast tumours using TCGA RNAseq data 
accessed through the UCSC Cancer Genomics Browser; 
they demonstrated that GPER expression is lower in 
primary tumours than normal breast tissues and that higher 
GPER expression in breast cancer patients was associated 
with increased survival, which is in agreement with our 
findings [19].
We performed artificial neural network analysis 
of transcriptomic array data to identify genes strongly 
associated with GPER expression. Interestingly, some 
well investigated proteins associated with breast cancer 
were identified, including notch-4, jagged-1 and CD34. 
Furthermore; links between some of the genes identified 
as associated with GPER expression have previously been 
described. The use of a GPER agonists has been shown 
to increase the levels of claudin-5 in the ischemic CA1 
in vivo [26] and also increased levels of CD34 in mouse 
xenograft models of breast cancer [27]. GPER has also 
been shown to be capable of stimulating adenylyl cyclase 
activity [28]. Although a direct link with notch-4 has not 
been described, GPER has been shown to engage notch-1 
signaling to alter gene expression and cell migration in 
breast cancer in vitro [29].
In summary, we have been able to demonstrate that 
low GPER protein and mRNA expression is associated 
with adverse survival in a large cohort of breast cancer 
patients. These findings suggest that GPER may have 
prognostic potential and may have utility as a therapeutic 
target and warrant further investigation in multi-centre 
studies.
MATERIALS AND METHODS
Immunohistochemistry patient cohort
This study is reported according to reporting 
recommendations for tumour marker prognostic studies 
(REMARK) criteria [30]. Ethical approval for this study 
was granted by Nottingham Research Ethics Committee 
2, under the title ‘Development of a molecular genetic 
classification of breast cancer’ (C202313). 1245 early 
stage invasive breast cancer patients treated at Nottingham 
University Hospitals between 1987 and 1998 were stained 
for GPER protein expression. All specimens have been 
handled according to The Royal College of Pathologists 
‘Pathology reporting of breast disease in surgical excision 
specimens incorporating the dataset for histological 
reporting of breast cancer’, with specimens sent 
immediately to the pathological laboratory after surgical 
resection and pre-dissected/incised. If incision of the fresh 
specimen was not possible, it was immediately placed in 
an adequate volume of fixative, at least twice that of the 
specimen.
All patients were managed in a standard manner, 
where all patients underwent a mastectomy or wide local 
excision, as decided by disease characteristics or patient 
choice, followed by radiotherapy if indicated. Patients 
received systemic adjuvant treatment on the basis of 
Nottingham Prognostic index (NPI), ER, and menopausal 
status. Patients with an NPI score less than 3.4 did not 
receive adjuvant treatment and patients with an NPI 
score of 3.4 were candidates for CMF chemotherapy 
(cyclophosphamide, methotrexate and 5-fluorouracil) if 
they were ER negative or premenopausal; and hormonal 
therapy if they were ER positive. Breast cancer specific 
survival was calculated as the time interval between 
primary surgery and death resultant from breast cancer.
Median survival for the cohort was 204 months 
as estimated by the reverse Kaplan-Meier method. The 
median age for this cohort was 55 years, ranging from 
24 to 72. In this cohort 16.1% of patients (199/1238) 
had grade one tumours, 33.6% (416/1238) had grade two 
tumours and 50.3% (623/1238) had grade three tumours. 
60.9% of patients (754/1238) had stage one tumours, 
30.1% of patients (373/1238) had stage two tumours and 
9.0% of patients (111/1238) had stage 3 tumours. 72.9% 
of patients (878/1205) were ER positive, 56.7% of patients 
(665/1173) were progesterone receptor (PgR) positive and 
13.6% (165/1213) of patients were HER2 positive. 58.2% 
(725/1245) were invasive ductal carcinomas, 17.3% 
(215/1245) were tubular mixed, 5.9% (74/1245) were 
classic lobular all other subcategories accounted for less 
than 5% of the studied cohort.
Immunohistochemistry
Immunohistochemistry was performed as previously 
described using a Novolink Polymer Detection kit (Leica) 
according to the manufacturers’ instructions [31]. In 
brief, slides were deparaffinised in xylene, followed 
by rehydration in ethanol and water. Antigen retrieval 
was performed in 0.01molL-1 sodium citrate buffer 
(pH6.0) in a microwave for 10 minutes at 750W and 10 
minutes at 450W. Tissue was treated with peroxidase 
block, washed with Tris-buffered saline (TBS), and then 
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treated with protein block solution. Rabbit polyclonal 
anti-GPER (Thermo Scientific (PA5-28647)) was used 
as primary antibody diluted 1:100 and was incubated 
on the tissue for one hour. Tissue was washed with TBS 
prior to the application of post primary solution, tissue 
was subsequently washed with TBS and then Novolink 
polymer solution was applied. Immunohistochemical 
reactions were developed using 3, 3’ diaminobenzidine as 
the chromogenic substrate and tissue was counterstained 
with haematoxylin. Tissue was dehydrated in ethanol 
and fixed in xylene. Positive and negative controls were 
included with each staining run and were comprised of 
breast tumour composite sections comprising grade 1 
and 2 early stage invasive tumour; negative controls 
had primary antibody omitted from each staining run 
(Supplementary Figure).
Gene expression patient cohort
Details of the METABRIC data set (n=1980) data 
set have been published elsewhere [32]. For genomic and 
transcriptional profiling, DNA and RNA were isolated 
from samples and hybridised to the Affymetrix SNP 6.0 
and Illumina HT-12 v3 platforms as described by Curtis et 
al (2012) [32]. In the METABRIC cohort ER positive and/
or lymph node negative patients did not receive adjuvant 
chemotherapy; ER negative and/or lymph node positive 
patients received adjuvant chemotherapy.
Immunohistochemistry scoring and statistical 
analyses
Assessment of immunohistochemical staining was 
conducted at 200x magnification following high resolution 
scanning using a Nanozoomer Digital Pathology Scanner 
(Hamamatsu Photonics). Staining in the cytoplasm was 
assessed using a semi-quantitative immunohistochemical 
H score; where staining intensity was assessed as 
none (0), weak (1), medium (2) or strong (3) over the 
percentage area of each staining intensity. Nuclear 
staining was assessed as the percentage of nuclei with 
any percentage intensity of staining. Greater than 30% of 
cores were double assessed, with both assessors blinded 
to clinical outcome and each other’s scores. The single 
measure intraclass correlation coefficient were above 0.7, 
indicating good concordance between scorers.
Statistical analysis was performed using IBM SPSS 
Statistics (version 24). Data was stratified based on breast 
cancer specific survival using X-Tile software [33]. All 
differences were deemed statistically significant at the 
level of P<0.05. The Pearson χ2 test of association was 
used to determine the relationship between categorised 
protein expression and clinicopathological variables. 
Survival curves were plotted according to the Kaplan-
Meier method with significance determined using the 
log-rank test. The primary endpoint of this study was to 
determine if GPER expression is associated with breast 
cancer specific survival.
Identification of genes associated with GPER 
expression
To further understand the molecular function of 
GPER in human breast cancer, the METABRIC series 
was analysed using a supervised artificial neural network. 
GPER expression was used as the supervising variable as 
described by Abdel-Fatah et al. [21]. The artificial neural 
network was conducted with multi-layer perceptron 
architecture and sigmoidal transfer function, where weights 
were updated by a back propagation algorithm. The top 
200 genes associated with GPER mRNA expression for 
probe 1 and probe 2 were used for further analysis.
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